JOHN RAE WUNDERLICH, MD
Medical Practice in Bethesda, MD
License number
Maryland G11772
Category
Medical Practice
Type
Specialist
Address
Address
10 Center Dr, Bethesda, MD 20892
Phone
(301) 496-9008
Personal information
See more information about JOHN RAE WUNDERLICH at radaris.comName
Address
Phone
10113 Parkwood Ter, Bethesda, MD 20814
41952 Loker Ct, Leonardtown, MD 20650
11238 Evans Trl, Beltsville, MD 20705
382 Doral Ct, Westminster, MD 21158
41952 Loker Ct, Leonardtown, MD 20650
Professional information
See more information about JOHN RAE WUNDERLICH at trustoria.com
Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy
Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Nonmyeloablative Lymphodepleting Chemotherapy
US Patent:
8287857, Oct 16, 2012
Filed:
Jul 8, 2011
Appl. No.:
13/178644
Inventors:
Mark E. Dudley - Silver Spring MD, US
Steven A. Rosenberg - Potomac MD, US
John R. Wunderlich - Bethesda MD, US
Steven A. Rosenberg - Potomac MD, US
John R. Wunderlich - Bethesda MD, US
Assignee:
The United States of America, as represented by the Secretary, Deparment of Health and Human Services - Washington DC
International Classification:
A01N 63/00, A61K 35/28, C12N 5/08
US Classification:
424 937, 424577, 4353723
Abstract:
A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.
Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Non-Myeloablative Lymphodepleting Chemotherapy
Immunotherapy With In Vitro-Selected Antigen-Specific Lymphocytes After Non-Myeloablative Lymphodepleting Chemotherapy
US Patent:
8034334, Oct 11, 2011
Filed:
Sep 5, 2003
Appl. No.:
10/526697
Inventors:
Mark E Dudley - Silver Spring MD, US
Steven A Rosenberg - Potomac MD, US
John R Wunderlich - Bethesda MD, US
Steven A Rosenberg - Potomac MD, US
John R Wunderlich - Bethesda MD, US
Assignee:
The United States of America as represented by the Secretary, Department of Health and Human Services - Washington DC
International Classification:
A01N 63/00, A61K 35/28, C12N 5/08
US Classification:
424 937, 424577, 4353723
Abstract:
A method of promoting the regression of a cancer in a mammal comprising: (i) administering to the mammal nonmyeloablative lymphodepleting chemotherapy, and (ii) subsequently administering: (a) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, and rapidly expanded in vitro only once, and, either concomitantly with the autologous T-cells or subsequently to the autologous T-cells, by the same route or a different route, a T-cell growth factor that promotes the growth and activation of the autologous T-cells, or (b) autologous T-cells, which have been previously isolated, selected for highly avid recognition of an antigen of the cancer, the regression of which is to be promoted, modified to express a T-cell growth factor that promotes the growth and activation of the autologous T-cells, and rapidly expanded in vitro only once, whereupon the regression of the cancer in the mammal is promoted.